Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer

Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer

BACKGROUND: The treatment of non-small cell lung cancer (NSCLC) has undergone changes that have improved the prognosis of patients. With the advent of immunotherapy, it has been possible to prolong significantly the overall and progression-free survival as well as quality of life. Nevertheless, its...

Full description

Bibliographic Details
Main Authors: R. Riera-Sala, A. Ibarra-Morales, J. Guzmán-Casta, R. Medrano-Guzmán, A. Dip-Borunda, A. Martin-Aguilar, R. Grajales-Álvarez, R. Correa-Cano, K. Elvira-Fabián, C. Sánchez-Ríos, A. Orzuna-Vázquez, J. Rovelo-Lima, L. Martínez-Barrera, J. Rodríguez-Cid, J. Alatorre-Alexander
Format: Article
Language:English
Published: Verduci Editore 2023-09-01
Series:World Cancer Research Journal
Subjects:
pseudoprogression
hyperprogression
immunotherapy
lung cancer
Online Access:https://www.wcrj.net/wp-content/uploads/sites/5/2023/09/e2660.pdf

Internet

https://www.wcrj.net/wp-content/uploads/sites/5/2023/09/e2660.pdf

Similar Items